In ERBB2+ breast cancer cells, which are resistant to Trastuzumab, a monoclonal antibody anticancer treatment, the depletion of CHD4 was shown to induce the cell’s sensitivity to this antibody by reducing ERBB2 signaling, affecting the autophagy process, and decreasing cell proliferation[93,95]. Here, ERBB2 is linked to breast carcinoma.